여성 건강 및 산부인과용 초음파 진단 기기 시장 : 수익 기반 유지 및 확대(2024-2035년)

Report Overview

This Marketstrat® Focus Report assesses the global OB/GYN and women's health ultrasound market from a 2024A base through 2035E. It sizes supplier revenue and links it to clinical demand, care settings, obstetric AI and supervised home use.

Our view: defend replacement and service relationships first, then earn more per account through specialty transducers, reporting and paid AI.

Key Questions Answered

• How can suppliers capture incremental value while women's health loses share of total ultrasound revenue?
• Which workflows, from detailed first-trimester anatomy to fertility monitoring, justify premium systems or recurring software?
• Which distribution route turns OB-AI clearances into paid adoption?
• What must a home prenatal ultrasound program prove before it can scale?

Market Snapshot

Women's health remains ultrasound's third-largest clinical application and grows in absolute terms, even as faster growth in cardiology and acute care lowers its share. Regional and country comparisons contrast replacement- and workflow-led spending in mature markets with a larger access-expansion opportunity in India.

Key Market Trends

• 1. Premium platforms are broadening. September 2026 launches from Samsung and Philips extend competition into maternal, gynecologic and early-pregnancy workflows.
• 2. Obstetric AI is moving onto the scanner. OEM marketplace and integration agreements widen access to the installed base; paid rollout remains a separate test.
• 3. The office is a priority channel, though not a uniform buyer. Fetal-medicine specialists and small general clinics need very different systems, support and financing.
• 4. Home monitoring is a pathway business. US authorization covers a defined prescription use; sponsor funding and clinician review decide whether programs scale.

Competitive Structure

The report profiles the dedicated women's health franchises of GE HealthCare (Voluson), Samsung Medison (HERA) and Mindray (Nuewa), plus Philips and shared-service rivals. Spotlights cover OB-AI and reporting developers such as Sonio, BrightHeart, Diagnoly and AS Software; Pulsenmore and Butterfly Network anchor the home section. A roles table sets each participant's execution priority.

What's Inside

Sizing and scenarios: Global pool, application, care-setting and hardware views, with downside, base and upside cases to 2035E.

AI readiness: An ARC-Index assessment by use case, a regulatory and partnership chronology through September 2026, and how OB AI gets paid.

Home monitoring: Status of the five requirements for scaling US home prenatal ultrasound.

Actions and signals: Recommendations by participant group and eight signals to watch over the next 12–24 months.

Who Should Read This Report

• Ultrasound OEM executives and women's health product managers
• Leaders of obstetric AI, reporting and home-monitoring companies
• Investors and corporate-development teams evaluating the category
• Health systems and OB/GYN practices planning equipment or AI purchases
• Fertility clinics considering home follicle monitoring

Why This Report

Most coverage stops at launches and clearance counts. This report ties those events to the revenue a supplier can book and separates regulatory decisions from company announcements. Recommendations are staged against observable commercial milestones.

Table of Contents

EXECUTIVE SUMMARY

• THE THREE NUMBERS THAT MATTER
• WHAT CHANGED THROUGH SEPTEMBER 2026
• IMPLICATIONS FOR DECISION-MAKERS

1. INTRODUCTION AND SCOPE

• 1.1 THE COMMERCIAL QUESTION
• 1.2 WHAT IS IN AND WHAT IS OUT
• 1.3 HOW TO READ THE NUMBERS

2. THE POOL: SIZING AND FORECAST, 2024A TO 2035E

• 2.1 THE GLOBAL POOL AND ITS SHARE DRIFT
• 2.2 WHERE CLINICAL DEMAND CREATES SUPPLIER VALUE
• 2.3 WHERE WOMEN’S HEALTH SITS IN THE APPLICATION MIX
• 2.4 REGIONAL AND COUNTRY MARKET COMPARISONS

3. DEMAND ARCHITECTURE: CLINICAL NEED, CARE SETTINGS AND SUPPLIER ECONOMICS

• 3.1 DEMOGRAPHIC CONTEXT AND THE REVENUE MECHANISM
• 3.2 OFFICE-BASED CARE AS A GROWTH CHANNEL
• 3.3 FIVE CLINICAL AND ACCESS OPPORTUNITIES
• 3.4 LABOR, EXAM QUALITY AND EVIDENCE REQUIREMENTS

4. THE AI LAYER IN WOMEN’S HEALTH

• 4.1 COMMERCIAL READINESS OF WOMEN’S HEALTH AI
• 4.2 CLINICAL FUNCTION, DEPLOYMENT AND OWNERSHIP
• 4.3 REGULATORY, PRODUCT AND PARTNERSHIP CHRONOLOGY
• 4.4 HOW OB AI GETS PAID

5. HOME MONITORING: A PATHWAY BUSINESS AHEAD OF REIMBURSEMENT

• 5.1 WHAT THE CATEGORY IS
• 5.2 FIVE REQUIREMENTS FOR SCALABLE ADOPTION
• 5.3 PURPOSE-BUILT PROGRAMS AND ADJACENT PLATFORMS

6. COMPETITIVE SET AND SPOTLIGHTS

• 6.1 OEM WOMEN’S HEALTH FRANCHISES
  • GE HealthCare
  • Samsung Medison
  • Mindray
  • Philips
  • Other OEM and shared-service alternatives
• 6.2 OB-AI AND REPORTING SPOTLIGHTS
  • Sonio (Samsung Medison)
  • BrightHeart
  • Diagnoly
  • Biotics AI, DeepEcho, and Ultrasound AI
  • AS Software and enterprise reporting
• 6.3 HOME AND ACCESS SPOTLIGHTS
  • Pulsenmore
  • Butterfly Network
• 6.4 COMPETITIVE READ

7. PLATFORM ECONOMICS AND PURCHASE MODELS

• 7.1 THE HARDWARE LINKAGE
• 7.2 PURCHASE MODELS AND THE OFFICE
• 7.3 SHARED-PLATFORM ECONOMICS WITH BREAST IMAGING

8. DEVELOPMENTS THROUGH SEPTEMBER 10, 2026

• 8.1 REPORTED FINANCIAL CONTEXT
• 8.2 REGULATORY, PRODUCT, POLICY, AND CAPITAL DEVELOPMENTS

9. IMPLICATIONS AND RECOMMENDED ACTIONS

• 9.1 OEM WOMEN’S HEALTH FRANCHISES
• 9.2 INDEPENDENT OB-AI VENDORS
• 9.3 HOME-MONITORING AND ACCESS PLATFORMS
• 9.4 INVESTORS AND CORPORATE DEVELOPMENT
• 9.5 PROVIDERS AND HEALTH SYSTEMS

10. SIGNALS TO WATCH AND SCENARIOS

• 10.1 MARKET SCENARIOS

11. METHODOLOGY, SOURCES AND INTERPRETATION

• 11.1 MODEL BASIS
• 11.2 SOURCES
• 11.3 RESEARCH CUTOFF AND REPORTING PERIODS
• 11.4 LIMITATIONS

APPENDIX A. REGIONAL AND COUNTRY OB/GYN ESTIMATES

APPENDIX B. SELECTED SOURCE REFERENCES